Cataplexy Drugs Market Share

On the basis of geographical analysis, the global cataplexy drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. North America industry is predicted to account for largest revenue share by 2036, propelled by high healthcare spending, rising number of cases of cataplexy, and strong presence of prominent companies in the region. According to the National Health Expenditure Accounts (NHEA), total healthcare spending in the United States grew 4.6 percent in 2019, reaching USD 3.8 trillion. As a share of the nation's Gross Domestic Product, health spending accounted for 17.7 percent.

Europe Analysis

Moreover, the cataplexy drugs market in Europe is also estimated to occupy a significant share owing to the rising number of R&D activities in the medical sector and growing investments of key industry players to develop and commercialize their drug candidates in the region.

Frequently Asked Questions (FAQ)

The major factors driving market growth are growing prevalence of cataplexy disorder around the world and rising geriatric population globally.

The market is anticipated to attain a notable CAGR over the forecast period, i.e., 2022 â€“ 2030.

Poor healthcare infrastructure of underdeveloped nations is estimated to hamper the market growth.

North America will provide more business opportunities for market growth owing to the high healthcare spending, and rising number of cases of cataplexy.

The major players in the market are Graymark Healthcare, Inc., Shire Plc., Teva Pharmaceutical USA Inc., Arena Pharmaceuticals, and others.

Cataplexy Drugs Market Share